Table 3.
Prospective clinical trials on sequential ex vivo liver perfusion
| Publication | Perfusion device | Donors | RCT | N | Group | Donor age | Recipient age | Recipient MELD | Perfusion time (min) | Peak AST (POD 1-7) (U/l) | EAD (%) | ICU (d) | HLS (d) | 1-year patient survival (%) | 1-year graft survival (%) | Biliary complication |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hoyer et al. (2016) | Liver Assist | DBD | No | 6 | COR | 58.5 (51–71) | 52.5 (43–65) | 18 (11–23) | 90 | n.a. | 0 | 3 (2–26) | 21.5 (14–103) | n.a. | n.a. | n.a. |
| 106 | SCS | 66.5 (42–88) | 55 (21–70) | 13 (6–28) | - | n.a. | 35.9 | 21.5 (0–161) | 19 (0–168) | n.a. | n.a. | n.a. | ||||
| van Leeuwen et al. (2019) | Liver Assist | DCD | No | 11 |
Perfusion (DCD) |
63 (52–72) | 61 (55–66) | 14 (13–15) | n.a. | 751 (483–1757) | n.a. | n.a. | n.a. | 100 | 100 | 1 |
| 24 | SCS (DCD) | 52 (48–56) | 56 (48–61) | 18 (11–24) | - | 2406 (1102-4573) | n.a. | n.a. | n.a. | 88 | 80 | 4 | ||||
| 36 | SCS (DBD) | 61 (47–66) | 52 (40–60) | 15 (10–22) | - | 1646 (627–2494) | n.a. | n.a. | n.a. | 100 | 100 | 3 |